Shahneen Sandhu
Shahneen Sandhu
Consultant Medical Oncologist
Verified email at petermac.org
Title
Cited by
Cited by
Year
DNA-repair defects and olaparib in metastatic prostate cancer
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ...
New England Journal of Medicine 373 (18), 1697-1708, 2015
15252015
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ...
New England Journal of Medicine 378 (19), 1789-1801, 2018
8702018
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ...
Annals of Oncology 28 (2), 368-376, 2017
4972017
The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
SK Sandhu, WR Schelman, G Wilding, V Moreno, RD Baird, S Miranda, ...
The lancet oncology 14 (9), 882-892, 2013
4832013
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
GV Long, V Atkinson, S Lo, S Sandhu, AD Guminski, MP Brown, ...
The Lancet Oncology 19 (5), 672-681, 2018
4482018
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ...
The Lancet Oncology 19 (6), 825-833, 2018
3932018
Enzalutamide with standard first-line therapy in metastatic prostate cancer
ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ...
New England Journal of Medicine 381 (2), 121-131, 2019
3542019
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, S Sandhu, A Patrikidou, C Pezaro, ...
Annals of oncology 24 (7), 1807-1812, 2013
3472013
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer
HI Scher, G Heller, A Molina, G Attard, DC Danila, X Jia, W Peng, ...
Journal of clinical oncology 33 (12), 1348, 2015
3282015
Envisioning the future of early anticancer drug development
TA Yap, SK Sandhu, P Workman, JS De Bono
Nature Reviews Cancer 10 (7), 514-523, 2010
2782010
Olaparib for metastatic castration-resistant prostate cancer
J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ...
New England Journal of Medicine 382 (22), 2091-2102, 2020
2742020
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
LJ Barber, S Sandhu, L Chen, J Campbell, I Kozarewa, K Fenwick, ...
The Journal of pathology 229 (3), 422-429, 2013
2652013
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
J Mezynski, C Pezaro, D Bianchini, A Zivi, S Sandhu, E Thompson, J Hunt, ...
Annals of Oncology 23 (11), 2943-2947, 2012
2542012
Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition
J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ...
Cancer discovery 7 (9), 1006-1017, 2017
2162017
Poly (ADP‐Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
TA Yap, SK Sandhu, CP Carden, JS De Bono
CA: a cancer journal for clinicians 61 (1), 31-49, 2011
2082011
UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas
SQ Wong, K Waldeck, IA Vergara, J Schröder, J Madore, JS Wilmott, ...
Cancer research 75 (24), 5228-5234, 2015
1932015
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
S Kamel, L Horton, L Ysebaert, M Levade, K Burbury, S Tan, ...
Leukemia 29 (4), 783-787, 2015
1932015
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
SK Sandhu, K Papadopoulos, PC Fong, A Patnaik, C Messiou, D Olmos, ...
Cancer chemotherapy and pharmacology 71 (4), 1041-1050, 2013
1762013
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ...
The Lancet Oncology 21 (1), 162-174, 2020
1642020
Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC …
HI Scher, G Heller, A Molina, TS Kheoh, G Attard, J Moreira, SK Sandhu, ...
Journal of Clinical Oncology 29 (18_suppl), LBA4517-LBA4517, 2011
1392011
The system can't perform the operation now. Try again later.
Articles 1–20